Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported an open-market sale of 3,361 shares of Common Stock at $3.35 per share to cover tax withholding on vested RSUs. After this tax-related sell-to-cover transaction, Trigg directly holds 102,342 shares and indirectly holds 41,666 shares through the Trigg 2002 Rev Trust and 584 shares through the Trigg Family Trust.
Outset Medical, Inc. executive vice president Marc Nash reported an open-market sale of 1,817 shares of common stock at $3.35 per share. After this transaction, he holds 39,988 shares of Outset Medical common stock.
According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of 4,384 shares underlying restricted stock units granted on March 15, 2021, July 24, 2023, January 12, 2024 and June 10, 2025. The filing states this was a “sell to cover” transaction and not a discretionary trade by Nash.
OM filing: a Form 144 notice reports proposed sale related to the settlement of 9,319 vested restricted stock units on 02/15/2026. The filing also lists three completed sales by Leslie Trigg totaling 15,709 shares across 01/07/2026, 01/20/2026, and 01/21/2026, with proceeds shown.
John Brottem reported sales of Common Stock via a Form 144 notice. The filing lists three dispositions: 244 shares on 01/07/2026, 9,314 shares on 01/20/2026, and 1,180 shares on 01/21/2026. The excerpt also shows the settlement of 5,032 vested restricted stock units on 02/15/2026 labeled as equity compensation.
Outset Medical, Inc. received an amended Schedule 13G/A from Durable Capital Partners reporting that it no longer beneficially owns any of the company’s common stock. The filing shows 0 shares beneficially owned and a 0.0% ownership of the class, with no voting or dispositive power reported.
The reporting person confirms its holdings are below 5% of the class and states that any securities referenced were acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Outset Medical.
Outset Medical, Inc. drew an updated ownership disclosure from institutional investors led by Health Sciences, LP. A group of related investment entities, including Health Sciences, LP, Health Sciences GP, LLC, Healthcare Growth Equity I GP, LLC, Partner Asset Management, LLC and Brian D. Grossman, reports beneficial ownership of 530,796 shares of Outset Medical common stock. Based on 18,153,090 shares outstanding as of November 6, 2025, this stake represents about 2.9% of the company’s outstanding shares, keeping the group below the 5% large-holder threshold. The reporting parties state that the securities were not acquired and are not held to change or influence control of Outset Medical.
Outset Medical, Inc. reports a major shareholder’s existing stake. A 10% owner associated with BML Investment Partners, L.P. reports indirect beneficial ownership of 1,902,201 shares of Outset Medical common stock as of 02/12/2026. These shares are held by BML Investment Partners, L.P., whose general partner is BML Capital Management, LLC, managed by Mr. Leonard. He exercises investment and voting control over the fund’s shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
BML Investment Partners, L.P. reported beneficial ownership of 1,902,201 shares of Outset Medical, Inc. common stock, representing 10.5% of the class as of the event dated 02/12/2026. All of these shares are held with shared voting and shared dispositive power; BML has no sole voting or sole dispositive power.
BML Investment Partners is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC, managed by Braden M. Leonard, who is deemed an indirect owner of the shares. The reporting persons certify the position is not held for the purpose of changing or influencing control of Outset Medical and disclaim being part of a statutory group.
Outset Medical is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, a compact console that integrates water purification, on-demand dialysate production and cloud connectivity for use in hospitals, clinics and homes.
The company emphasizes ease of use, reduced infrastructure needs and rich data analytics through platforms like TabloHub, MyTablo and TabloDash to improve operational efficiency and device uptime. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was approximately $334.7 million, and 18,311,626 shares were outstanding as of February 10, 2026.
Outset operates in a competitive dialysis market against large players such as Fresenius and DaVita, relies on a sizable global patent portfolio expiring between June 2027 and April 2042, and manufactures primarily in Mexico under ISO 13485 standards. Tablo is regulated as a Class II device with multiple 510(k) clearances, including a next‑generation platform cleared in January 2026, and prior FDA inspection and warning letter issues have been closed. Revenue is heavily influenced by U.S. reimbursement frameworks, notably the ESRD Prospective Payment System base rate of $281.71 per treatment for 2026 and evolving Medicare payment models and health‑reform policies.
Outset Medical reported full-year 2025 revenue of $119.5 million, up 5% from 2024, with gross margin improving to 39.1% from 33.9%. Net loss narrowed to $81.7 million versus $128.0 million a year earlier as operating expenses fell significantly.
Recurring revenue from Tablo consumables and services grew 6% to $88.7 million, and total cash, including investments, reached $172.8 million at year-end. The company also received FDA clearance for its next-generation Tablo platform. For 2026, it guides revenue to $125–$130 million and expects non-GAAP gross margin in the low to mid-40% range.